Literature DB >> 3367167

The significance of simultaneous estimation of serum creatine kinase and myoglobin in neuromuscular diseases.

P Diószeghy1, F Mechler.   

Abstract

Serum creatine kinase (CK) and myoglobin (Mb) levels were measured in patients with different neuromuscular diseases, carriers of X-linked Duchenne-type muscular dystrophy and normal volunteers. The highest levels were found in Duchenne dystrophy and both values decreased in parallel with age. In patients suffering from limb-girdle dystrophy the increases in CK activity and Mb concentration were also pronounced. However, there were families with normal and others with elevated CK and Mb levels in facioscapulohumeral dystrophy. In neurogenic atrophies both CK and Mb levels generally increased only slightly. Serum Mb and CK levels have similar values as indicators of muscle damage in primary and secondary skeletal muscle disorders. The serum Mb level helps in the detection of carriers but is not more sensitive than CK measurement.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367167     DOI: 10.1007/bf00314312

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

1.  Effect of oral contraceptive pills on the level of creatine phosphokinase with regard to carrier detection in Duchenne muscular dystrophy.

Authors:  J Simpson; H Zellweger; L F Burmeister; R Christee; M K Nielsen
Journal:  Clin Chim Acta       Date:  1974-04       Impact factor: 3.786

2.  The detection of carriers of X-linked muscular dystrophy genes. A review of some methods studied in Newcastle upon Tyne.

Authors:  D Gardner-Medwin; R J Pennington; J N Walton
Journal:  J Neurol Sci       Date:  1971-08       Impact factor: 3.181

3.  [On the value of radioimmunologic myoglobin determination in skeletal muscle disorders (author's transl)].

Authors:  W R Kiessling; R Beckmann
Journal:  Fortschr Neurol Psychiatr       Date:  1981-12       Impact factor: 0.752

4.  Carrier detection in Duchenne muscular dystrophy. Evidence from a study of obligatory carriers and mothers of isolated cases.

Authors:  J R Sibert; P S Harper; R J Thompson; R G Newcombe
Journal:  Arch Dis Child       Date:  1979-07       Impact factor: 3.791

5.  Serum myoglobin in primary and secondary skeletal muscle disorders.

Authors:  W R Kiessling; K Ricker; K W Pflughaupt; H G Mertens; I Haubitz
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

6.  Serum myoglobin in muscular dystrophy and carrier detection.

Authors:  L V Nicholson
Journal:  J Neurol Sci       Date:  1981-09       Impact factor: 3.181

7.  Variation of serum myoglobin levels in normal individuals. With reference to the use of myoglobin measurements for the detection of women carrying genes for the X-linked muscular dystrophies.

Authors:  L V Nicholson; T J Walls
Journal:  J Neurol Sci       Date:  1983-12       Impact factor: 3.181

8.  The significance of the estimation of serum myoglobin in neuromuscular diseases.

Authors:  E A Hische; H J van der Helm
Journal:  J Neurol Sci       Date:  1979-10       Impact factor: 3.181

9.  A radioimmunoassay for human serum myoglobin: method development and normal values.

Authors:  T G Rosano; M A Kenny
Journal:  Clin Chem       Date:  1977-01       Impact factor: 8.327

  9 in total
  2 in total

Review 1.  Exercise-induced muscle damage and adaptation.

Authors:  C B Ebbeling; P M Clarkson
Journal:  Sports Med       Date:  1989-04       Impact factor: 11.136

2.  Skeletal muscle CK-B activity in neurogenic muscular atrophies.

Authors:  E Vretou-Jockers; D Vassilopoulos
Journal:  J Neurol       Date:  1989-07       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.